Toripalimab Plus Chemotherapy as First-Line Treatment for Advanced Esophageal Cancer Reached Primary Endpoints in Phase III Clinical Study | Comunicados | Edición USA
22 abr 2021 Toripalimab Plus Chemotherapy as First-Line Treatment for Advanced Esophageal Cancer Reached Primary Endpoints in Phase III Clinical Study SHANGHAI, China, April 22, 2021 (GLOBE NEWSWIRE) -- Junshi Biosciences (HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies, announced today that the Independent Data Monitoring Committee (IDMC) has determined that toripalimab in combination with paclitaxel/cisplatin as the first-line treatment for patients with advanced esophageal squ...